For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
0
views
19
references
 Top references
cited by
0
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
0 collections
    0
    shares
      136
      similar
       All similar
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Application value of the treatment of breast cancer bone metastases with radioactive seed 125I implantation under CT-guidance

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          To investigate the application value of the treatment of breast cancer bone metastases with radioactive seed 125I implantation under CT-guidance.

          Methods

          A total of 90 patients with breast cancer admitted to our hospital from January 2017 to January 2018 were selected as the research objects and were divided into control group and experimental group according to random grouping, with 45 cases in each group. Conventional treatment was used in the control group, while the treatment of radioactive seed 125I implantation under CT-guidance was used in the experimental group. The clinical efficacy, pain intensity and levels of carcinoembryonic antigen (CEA), carcinoembryonic antigen 153 (CA153), carbohydrate antigen (CA125) in the two groups were compared.

          Results

          As for the pain intensity, it was evidently lower in the experimental group after treatment than that in the control group ( P < 0.05); as for the total effective rate, it was obviously higher in the experimental group after treatment than that in the control group ( P < 0.05); as for the levels of CEA, CA153 and CA125, the data in the experimental group after treatment were much lower than the control group ( P < 0.05).

          Conclusion

          Radioactive seed 125I implantation under CT-guidance can effectively improve the effect of the treatment of breast cancer bone metastases. It has curative efficacy and it is worth promoting and using.

          Related collections

          Most cited references19

          • Record: found
          • Abstract: not found
          • Article: not found

          Breast Osteoblast-like Cells: A Reliable Early Marker for Bone Metastases From Breast Cancer

          Umberto Tarantino, Manuel Scimeca, Chiara Antonacci … (2018)
          Article 0 comments Cited 29 times – based on 0 reviews     Review now
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Cutting to the Chase: How Matrix Metalloproteinase-2 Activity Controls Breast-Cancer-to-Bone Metastasis

            Marilena Tauro, Conor Lynch (2018)
            Bone metastatic breast cancer is currently incurable and will be evident in more than 70% of patients that succumb to the disease. Understanding the factors that contribute to the progression and metastasis of breast cancer can reveal therapeutic opportunities. Matrix metalloproteinases (MMPs) are a family of proteolytic enzymes whose role in cancer has been widely documented. They are capable of contributing to every step of the metastatic cascade, but enthusiasm for the use of MMP inhibition as a therapeutic approach has been dampened by the disappointing results of clinical trials conducted more than 20 years ago. Since the trials, our knowledge of MMP biology has expanded greatly. Combined with advances in the selective targeting of individual MMPs and the specific delivery of therapeutics to the tumor microenvironment, we may be on the verge of finally realizing the promise of MMP inhibition as a treatment strategy. Here, as a case in point, we focus specifically on MMP-2 as an example to show how it can contribute to each stage of breast-cancer-to-bone metastasis and also discuss novel approaches for the selective targeting of MMP-2 in the setting of the bone-cancer microenvironment.
            Article 0 comments Cited 27 times – based on 0 reviews     Review now
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Incidence proportions and prognosis of breast cancer patients with bone metastases at initial diagnosis

              Yue Gong, Jing Zhang, Peng Ji … (2018)
              Abstract Introduction Population‐based data on the incidence and prognosis of bone metastases at diagnosis of breast cancer are currently limited. Hence, we conducted this study to analyze the incidence proportions and prognostic factors of patients with breast cancer and bone metastases at the time of cancer diagnosis. Materials and methods Patients with primary invasive breast cancer and bone metastases at initial diagnosis between 2010 and 2014 were identified using the Surveillance, Epidemiology, and End Results (SEER) dataset and Fudan University Shanghai Cancer Center (FUSCC) cohort. Multivariable logistic regression was performed to identify predictors of the presence of bone metastases at diagnosis. Univariate and multivariate analyses were performed to determine the effects of each variable on survival. Results Of 229, 195 patients from SEER database included in the analysis, 8295 patients had bone metastases at initial diagnosis, reflecting 3.6% of the entire study population, and 65.1% of the subset with metastatic disease to any distant site. Patients with hormone receptor (HR)‐positive human epidermal growth factor receptor 2 (HER2)‐negative represented the highest incidence proportions among patients with metastatic disease (73.9%). Among entire cohort, multivariable logistic regression identified eight factors as predictors of the presence of bone metastases at diagnosis. Median OS for the patients with bone metastases in SEER and FUSCC cohorts was 30.0 and 68.2 months, respectively. Patients with HR‐positive HER2‐positive subtype had the longest median OS, and patients with triple‐negative subtype showed the shortest median OS. Multivariable Cox model in SEER cohort confirmed age, histology, grade, tumor subtype, extraosseous metastatic sites, history of primary surgery, insurance status, marital status, and income as independent prognostic factors for both OS and BCSS. Conclusions The findings of this study provide population‐based estimates of the incidence and prognosis for patients with bone metastases at initial diagnosis of breast cancer.
              Article 0 comments Cited 20 times – based on 0 reviews     Review now
                Bookmark
                All references

                Author and article information

                Contributors
                Maobo Wang: yilinluncan403ie@163.com
                Journal
                Journal ID (nlm-ta): BMC Med Imaging
                Journal ID (iso-abbrev): BMC Med Imaging
                Title: BMC Medical Imaging
                Publisher: BioMed Central (London )
                ISSN (Electronic): 1471-2342
                Publication date (Electronic): 4 January 2022
                Publication date PMC-release: 4 January 2022
                Publication date Collection: 2022
                Volume: 22
                Electronic Location Identifier: 3
                Affiliations
                [1 ]Department of Radiology, Zibo Hospital of Shandong Guoxin HealthCare Group, Zibo, China
                [2 ]Department of Radiology, Shandong Provincial Maternal and Child Health Care Hospital, No. 238, Jingshi East Road, Jinan City, 250014 Shandong Province China
                Article
                Publisher ID: 726
                DOI: 10.1186/s12880-021-00726-w
                PMC ID: 8725351
                PubMed ID: 34983423
                SO-VID: b0b9f883-7cdb-4799-8e2c-2dfd4bff0e26
                Copyright © © The Author(s) 2021
                License:

                Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

                History
                Date received : 4 November 2021
                Date accepted : 25 November 2021
                Categories
                Subject: Research
                Custom metadata
                issue-copyright-statement © The Author(s) 2022

                ScienceOpen disciplines: Radiology & Imaging
                Keywords: ct-guidance,radioactive seed 125i implantation,breast cancer,bone metastases
                Data availability:
                ScienceOpen disciplines: Radiology & Imaging
                Keywords: ct-guidance, radioactive seed 125i implantation, breast cancer, bone metastases

                Comments

                Comment on this article